Effectiveness of intra-thecal methotrexate in refractory Anti-N-methyl-d-aspartate receptor encephalitis.
Autoimmune encephalitis2
Intra-thecal immunotherapy4
Methotrexate3
Refractory NMDA encephalitis1
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
07 Jul 2023
07 Jul 2023
Historique:
received:
17
05
2023
accepted:
22
06
2023
medline:
10
7
2023
pubmed:
8
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
Anti-N-methyl-d-aspartate "anti-NMDA" receptor encephalitis is one of the most common autoimmune encephalitis for which first- and second-line therapies have been recommended following international consensus. However, some refractory cases do not respond to the first- and second-line therapy and require further immune-modulatory therapies such as intra-thecal methotrexate. In this study, we reviewed six confirmed cases of refractory anti-NMDA receptor encephalitis from two tertiary centers in Saudi Arabia that required escalation of treatment and received a six-month course of intra-thecal methotrexate. The aim of this study was to evaluate the effectiveness of intra-thecal methotrexate as immunomodulatory therapy for refractory anti-NMDA receptor encephalitis. We retrospectively evaluated six confirmed cases of refractory anti-NMDA receptor encephalitis who did not improve after first- and second-line therapy and received monthly intra-thecal methotrexate treatment course for six consecutive months. We reviewed patient demography, underlying etiologies, and compared their modified Rankin score prior to receiving intra-thecal methotrexate and six months after completing the treatment. Three of the six patients showed a marked response to intra-thecal methotrexate with a modified Rankin scale of 0-1 at 6-month follow-up. None of the patients experienced any side effects during or after intra-thecal methotrexate treatment, and no flareups were observed. Intra-thecal methotrexate may be a potentially effective and relatively safe escalation option for immunomodulatory therapy of refractory anti-NMDA receptor encephalitis. Future studies on intra-thecal methotrexate -specific treatment regimens may further support its utility, efficacy, and safety in treating refractory anti-NMDA receptor encephalitis.
Sections du résumé
BACKGROUND
BACKGROUND
Anti-N-methyl-d-aspartate "anti-NMDA" receptor encephalitis is one of the most common autoimmune encephalitis for which first- and second-line therapies have been recommended following international consensus. However, some refractory cases do not respond to the first- and second-line therapy and require further immune-modulatory therapies such as intra-thecal methotrexate. In this study, we reviewed six confirmed cases of refractory anti-NMDA receptor encephalitis from two tertiary centers in Saudi Arabia that required escalation of treatment and received a six-month course of intra-thecal methotrexate. The aim of this study was to evaluate the effectiveness of intra-thecal methotrexate as immunomodulatory therapy for refractory anti-NMDA receptor encephalitis.
METHODS
METHODS
We retrospectively evaluated six confirmed cases of refractory anti-NMDA receptor encephalitis who did not improve after first- and second-line therapy and received monthly intra-thecal methotrexate treatment course for six consecutive months. We reviewed patient demography, underlying etiologies, and compared their modified Rankin score prior to receiving intra-thecal methotrexate and six months after completing the treatment.
RESULTS
RESULTS
Three of the six patients showed a marked response to intra-thecal methotrexate with a modified Rankin scale of 0-1 at 6-month follow-up. None of the patients experienced any side effects during or after intra-thecal methotrexate treatment, and no flareups were observed.
CONCLUSION
CONCLUSIONS
Intra-thecal methotrexate may be a potentially effective and relatively safe escalation option for immunomodulatory therapy of refractory anti-NMDA receptor encephalitis. Future studies on intra-thecal methotrexate -specific treatment regimens may further support its utility, efficacy, and safety in treating refractory anti-NMDA receptor encephalitis.
Identifiants
pubmed: 37420168
doi: 10.1186/s12883-023-03301-8
pii: 10.1186/s12883-023-03301-8
pmc: PMC10327370
doi:
Substances chimiques
Methotrexate
YL5FZ2Y5U1
Antibodies
0
Receptors, N-Methyl-D-Aspartate
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
261Informations de copyright
© 2023. The Author(s).
Références
Dev Med Child Neurol. 2015 Jan;57(1):95-9
pubmed: 25040285
J Int Med Res. 2020 Oct;48(10):300060520925666
pubmed: 33100078
Eur J Paediatr Neurol. 2019 Jan;23(1):7-18
pubmed: 30318435
Pediatr Neurol. 2014 Jun;50(6):625-9
pubmed: 24742799
J Neurol Sci. 2015;353(1-2):169-71
pubmed: 25912173
Front Pediatr. 2021 Apr 22;9:605042
pubmed: 33968840
CNS Drugs. 2022 Sep;36(9):919-931
pubmed: 35917105
J Pediatr Neurosci. 2017 Apr-Jun;12(2):130-134
pubmed: 28904568
Blood. 1975 Feb;45(2):189-95
pubmed: 1091308
Neurotherapeutics. 2016 Oct;13(4):824-832
pubmed: 27215218
Neurol Neuroimmunol Neuroinflamm. 2021 Feb 15;8(2):
pubmed: 33589542
J Clin Neurol. 2016 Jan;12(1):1-13
pubmed: 26754777
Chin Med J (Engl). 2018 Jan 20;131(2):156-160
pubmed: 29336363
Adv Pharmacol. 2018;82:235-260
pubmed: 29413523
Indian J Pediatr. 2016 Jul;83(7):628-33
pubmed: 26801499
Acta Neurol Scand. 2017 Oct;136(4):298-304
pubmed: 28028820
Rev Neurol. 2013 Nov 1;57(9):405-10
pubmed: 24150952
Neurol Neuroimmunol Neuroinflamm. 2021 Jul 22;8(5):
pubmed: 34301820
BJPsych Bull. 2015 Feb;39(1):19-23
pubmed: 26191419
J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):757-768
pubmed: 33649022
J Neurosci. 2010 Apr 28;30(17):5866-75
pubmed: 20427647
Int Med Case Rep J. 2021 May 24;14:343-347
pubmed: 34079388
Front Immunol. 2021 Dec 16;12:790962
pubmed: 34975890
Eur J Paediatr Neurol. 2017 Sep;21(5):795-797
pubmed: 28655493